MX2018014966A - Peptidos monolipidados resistentes a proteasas. - Google Patents
Peptidos monolipidados resistentes a proteasas.Info
- Publication number
- MX2018014966A MX2018014966A MX2018014966A MX2018014966A MX2018014966A MX 2018014966 A MX2018014966 A MX 2018014966A MX 2018014966 A MX2018014966 A MX 2018014966A MX 2018014966 A MX2018014966 A MX 2018014966A MX 2018014966 A MX2018014966 A MX 2018014966A
- Authority
- MX
- Mexico
- Prior art keywords
- protease
- peptides
- resistant
- amino acids
- lipidated peptides
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 7
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 6
- 108091005804 Peptidases Proteins 0.000 title abstract 4
- 239000004365 Protease Substances 0.000 title abstract 4
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title abstract 4
- 150000001413 amino acids Chemical class 0.000 abstract 3
- 125000000539 amino acid group Chemical group 0.000 abstract 1
- 230000029226 lipidation Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La presente invención proporciona péptidos resistentes a proteasas, métodos de preparación de tales péptidos, así como composiciones que comprenden péptidos resistentes a proteasas y métodos de tratamiento que utilizan tales péptidos. Se ha determinado que una combinación de lipidación de ciertos residuos de aminoácidos y sustitución de aminoácidos alternativos por aminoácidos naturales y aminoácidos adicionales añadidos a la cadena peptídica produce péptidos resistentes a proteasas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662347693P | 2016-06-09 | 2016-06-09 | |
| PCT/EP2017/063905 WO2017211922A2 (en) | 2016-06-09 | 2017-06-08 | Protease-resistant mono-lipidated peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2018014966A true MX2018014966A (es) | 2019-08-14 |
Family
ID=59078034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018014966A MX2018014966A (es) | 2016-06-09 | 2017-06-08 | Peptidos monolipidados resistentes a proteasas. |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3468987A2 (es) |
| JP (1) | JP2019525732A (es) |
| KR (1) | KR20190017017A (es) |
| CN (1) | CN109195984A (es) |
| AU (1) | AU2017277594A1 (es) |
| BR (1) | BR112018072968A2 (es) |
| CA (1) | CA3025592A1 (es) |
| IL (1) | IL263292A (es) |
| MX (1) | MX2018014966A (es) |
| WO (1) | WO2017211922A2 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7239566B2 (ja) * | 2017-09-22 | 2023-03-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
| WO2019193576A1 (en) | 2018-04-05 | 2019-10-10 | Sun Pharmaceutical Industries Limited | Novel glp-1 analogues |
| WO2022159395A1 (en) | 2021-01-20 | 2022-07-28 | Viking Therapeutics, Inc. | Compositions and methods for the treatment of metabolic and liver disorders |
| EP4259647A4 (en) | 2021-09-15 | 2025-03-26 | Viking Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES |
| TW202346323A (zh) * | 2022-02-07 | 2023-12-01 | 英商梅迪繆思有限公司 | 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090318353A1 (en) * | 2006-08-25 | 2009-12-24 | Novo Nordisk A/S | Acylated Exendin-4 Compounds |
| JP2017502003A (ja) * | 2013-12-13 | 2017-01-19 | メディミューン リミテッド | プロテアーゼ耐性ペプチド |
| TWI726889B (zh) * | 2015-06-10 | 2021-05-11 | 英商梅迪繆思有限公司 | 蛋白酶抗性之脂化肽 |
-
2017
- 2017-06-08 KR KR1020197000408A patent/KR20190017017A/ko not_active Withdrawn
- 2017-06-08 WO PCT/EP2017/063905 patent/WO2017211922A2/en not_active Ceased
- 2017-06-08 BR BR112018072968-0A patent/BR112018072968A2/pt not_active Application Discontinuation
- 2017-06-08 MX MX2018014966A patent/MX2018014966A/es unknown
- 2017-06-08 AU AU2017277594A patent/AU2017277594A1/en not_active Abandoned
- 2017-06-08 JP JP2018562568A patent/JP2019525732A/ja active Pending
- 2017-06-08 CA CA3025592A patent/CA3025592A1/en not_active Abandoned
- 2017-06-08 EP EP17731089.3A patent/EP3468987A2/en not_active Withdrawn
- 2017-06-08 CN CN201780032425.2A patent/CN109195984A/zh active Pending
-
2018
- 2018-11-26 IL IL263292A patent/IL263292A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017277594A1 (en) | 2019-02-07 |
| CN109195984A (zh) | 2019-01-11 |
| EP3468987A2 (en) | 2019-04-17 |
| JP2019525732A (ja) | 2019-09-12 |
| CA3025592A1 (en) | 2017-12-14 |
| KR20190017017A (ko) | 2019-02-19 |
| BR112018072968A2 (pt) | 2019-02-19 |
| WO2017211922A3 (en) | 2018-01-18 |
| WO2017211922A2 (en) | 2017-12-14 |
| IL263292A (en) | 2018-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125302T1 (el) | Συναγωνιστες γλυκαγονης και glp-1 για την αγωγη της παχυσαρκιας | |
| MX2017009595A (es) | Compuestos antisenescentes y usos de los mismos. | |
| SG10201805039UA (en) | Protease resistant peptides | |
| PH12017502259A1 (en) | Protease-resistant lipidated glp-1 analogs | |
| MX2018014966A (es) | Peptidos monolipidados resistentes a proteasas. | |
| MX351414B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| CR20130667A (es) | Composiciones que contienen, mètodos que involucran, y usos derivados de dolastatina unidos a aminoàcidos no naturales | |
| WO2015027259A3 (de) | Polypeptid zur hydrolytischen spaltung von zearalenon und/oder zearalenon-derivaten, isoliertes polynukleotid davon sowie einen zusatzstoff enthaltendes polypeptid, verwendung desselben sowie verfahren | |
| EA201990071A1 (ru) | Композиция пептидной вакцины | |
| PH12018502465A1 (en) | Mic-1 compounds and use thereof | |
| EA201490735A1 (ru) | Лечение дегенеративного заболевания сустава | |
| NZ721015A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
| MX2019007152A (es) | Peptido novedoso. | |
| SG10201806926YA (en) | Method for masking bitterness of composition containing collagen peptide | |
| EA201792362A1 (ru) | Композиции и способы для лечения целиакии спру | |
| PH12017501070B1 (en) | Peptides and their use in the treatment of skin | |
| BR112017018703A2 (pt) | peptídeo derivado de gpc3, composição farmacêutica para tratamento ou prevenção de câncer usando o mesmo, indutor de imunidade, e método para produzir células de apresentação de antígeno | |
| MX2019003970A (es) | Péptidos de arginasa inmunogénicos. | |
| EA202091007A1 (ru) | Способ снижения времени восстановления высушенных распылением белковых составов | |
| MX2015002279A (es) | Peptido pntx(19) sintético, composición farmacéutica.y uso. | |
| EP3925968A3 (en) | Hsp70-derived peptide, pharmaceutical composition for treating or preventing cancer using same, immunity inducer, and method for producing antigen-presenting cell | |
| NZ744289A (en) | Composition containing amino acids | |
| SG11201804902UA (en) | A composition for improving memory, learning ability, and cognitive ability | |
| EA201692440A1 (ru) | Пролин-специфичная эндопротеаза и ее применение |